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ABSTRACT
The Trypanosoma and Toxoplasma spp, are etiological agents of diseases capable of causing significant
morbidity, mortality and economic burden, predominantly in developing countries. Currently, there are
no effective vaccines for the diseases caused by these parasites; therefore, therapy relies heavily on
antiprotozoal drugs. However, the treatment options for these parasitic diseases are limited, thus
underscoring the need for new anti-protozoal agents. Here, we investigated the anti-parasite action of
nanoparticles. We found that the nanoparticles have strong and selective in vitro activity against
T. b. brucei but moderate in vitro activity against T. congolense and T. evansi. An estimation of the
in vitro anti-Trypanosoma efficacy showed that the nanoparticles had 200-fold selective activity
against the parasite versus mammalian cells. Moreover, the nanoparticle alloys moderately suppressed
the in vitro growth of T. gondii by 60%. In our in vivo study, the nanoparticles appeared to exhibit a
trypanostatic effect, but did not totally suppress the rat parasite burden, thereby failing to appreciably
extend the survival time of infected animals compared with the untreated control. In conclusion, this is
the first study to demonstrate the selective in vitro anti-Trypanosoma action of nanoparticles and thus
supports the potential of nanoparticles as alternative anti-parasitic agents.
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Introduction
Trypanosoma and Toxoplasma are protozoan parasites
responsible for diseases that cause significant morbidity,
mortality and economic burden, predominantly in developing
countries [1–3]. For example, African trypanosomosis is a
lethal infectious disease for both humans and livestock; an
epidemic of this infection would have a major impact on the
economic development of sub-Saharan Africa [4]. The causa-
tive agents are hemoflagellated protozoan parasites
(i.e. Trypanosoma species), which elicit fatal diseases in
African mammalian hosts. The human African trypanosomia-
sis (HAT, also called sleeping sickness) is caused by
Trypanosoma brucei rhodesiense and Trypanosoma brucei gam-
biense, whereas bovine Trypanosomosis or nagana is caused
by Trypanosoma brucei brucei [5–7]. Trypanosoma infection
is fatal if left untreated either in humans or animals.
Chemotherapy is a major means of controlling the infection;
however, the available treatment options have various short-
comings including limited efficacy, toxicity and the emer-
gence of resistant strains of trypanosomes [2,8]. Melarsoprol,
one of the few drugs effective against the second stage of
the disease, is reported to cause encephalopathy in 10–15%
of patients, and approximately 40% of these cases are fatal
[9,10]. These highlight the need for innovative strategies to
combat trypanosomosis, which puts the health of more than
60 million people in the sub-Saharan Africa at risk annually
[11]. Consequently, the lack of effective anti-Trypanosoma
therapies, coupled with unsuccessful attempts at vaccine
development due to antigenic variation, has stimulated
the search for new chemotherapy for trypanosomosis.
Therefore, new candidate drugs against trypanosomosis are
urgently needed.
Toxoplasmosis is another parasitic disease that constitutes
a huge public health challenge. Toxoplasmosis, which is
caused by the intracellular parasite Toxoplasma gondii, is a
common parasitic disease capable of infecting a range of
hosts, including nearly one-third of the human population
[12]. Current treatment options for toxoplasmosis patients
are limited; they include the use of anti-malarial drugs or
antibiotics, which often cause significant side effects [13].
Thus, as with Trypanosomosis, this infection represents large
global burden that is further enhanced by the shortcomings
of available therapeutic options. These factors underscore the
need for better anti-T. gondii treatment and/or new
treatment approaches. Taken together, new antiprotozoals
are urgently required, as most of the current treatment
options have limitations such as poor efficacy, drug
resistance, toxicity, high cost or unsuitable pharmacokinetic
properties [1].
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The use of nanomaterials or nanoparticles for biomedical
purposes is on the rise particularly because of their nanoscale
size, which affords unique and remarkable properties that
can be explored for various biomedical purposes [14]. For
example, nanoparticles such as silver (AgNP), gold (AuNP)
and platinum (PtNP) have good solubility and have been
shown to have anti-microbial [15,16] and anti-parasitic activ-
ities [3,17–19]. Separate studies have demonstrated that
these nanoparticles also have other bioactivies such as select-
ive binding and enzyme inhibition [20–22]. We recently
reported the potential of AuNP and AgNP to selectively
inhibit recombinant target enzymes from T. b. brucei [23,24].
In addtion, we reported the potential of inorganic nanopar-
ticles to restrict the growth of T. gondii [3,25]. Taken
together, these findings support the further biological profil-
ing of nanoparticles in experimental parasitic infection. It is
against this backdrop that the present study investigated the
anti-Trypanosoma potential of several metal nanoparticles
in vitro and in vivo. Alloys of these nanparticles were also
screened for anti-T. gondii activity in vitro.
Materials and methods
Nanoparticle synthesis and characterization
The nanoparticles were prepared as previously reported;
AuNP, AgNP and PtNP were synthesized from HAuCl4, AgNO3
and H2PtCl6, respectively, and stabilized with tannic acid/
ethanol [23,24,26,27]. Alloys of the nanoparticles (Ag-Au-Pt-
NP, Ag-Pt-NP, Au-Pt-NP and Ag-Au-NP) were synthesized as
previously reported [27] with little modification. Briefly, the
individual salts (HAuCl4, AgNO3 or H2PtCl6) were reduced one
after the other in ethanol using microwave-assisted heating
to produce Ag-Au-Pt-NP, Ag-Pt-NP, Au-Pt-NP or Ag-Au-NP.
The tryptophan-nanoparticle conjugates (AuNPTRP and
AgNPTRP) were prepared as previously described and charac-
terized [28]. The resulting coloured solutions (AgNP, pale
yellow; AuNP, ruby red; PtNP, dark brown; Ag-Au-Pt,-NP,
dark-brown; Ag-Pt-NP, dark brown; Au-Pt-NP, dark wine red;
Ag-Au-NP, brownish wine red; AuNPTRP, wine-red; and
AgNPTRP, pale yellow) were filtered through 0.22-lm filters
and characterized by use of UV/Vis spectrophotometry,
inductively coupled plasma optical emission spectrometry
(ICP-OES), energy dispersive X-ray spectroscopy (EDX) and
transmission electron microscopy (TEM) [23,24,26,27,29].
In vitro experiments
Trypanosoma parasites
Parasite culture conditions were as previously reported [8].
Briefly, Trypanosoma congolense IL3000, a savannah-type
strain isolated near the Kenya/Tanzania border in 1966,
Trypanosoma evansi Tansui and T. b. brucei GUTat 3.1 were
maintained in the bloodstream form (BSF) in HMI-9 medium
[30] and propagated at 33 C (T. congolense) and 37 C
(T. evansi and T. b. brucei) in the air. The culture medium
included Iscove’s modified Dulbecco’s medium (Sigma-
Aldrich Japan, Tokyo, Japan) supplemented with 20% foetal
bovine serum (FBS; Gibco, Invitrogen, Waltham, MA), 60mM
HEPES (Sigma-Aldrich, St Louis, MO), 1mM pyruvic acid
sodium salt (Sigma-Aldrich, St Louis, MO), 0.1mM bathocu-
proine (Sigma-Aldrich, St Louis, MO), 1mM hypoxanthine,
16 lM thymidine (HT supplement: Thermo Fisher Scientific
K.K., Yokohama, Japan), 10lg/L insulin, 5.5lg/L transferrin,
6.7 ng/L sodium selenite (ITS-X: Thermo Fisher Scientific,
Pittsburgh, PA), 0.0001% 2-b-mercaptoethanol (Sigma-Aldrich)
and 2mM L-cysteine (Sigma-Aldrich, St Louis, MO). The
cultures were maintained by replacing the entire supernatant
with fresh medium every other day.
In vitro evaluation of the anti-trypanosoma activity of
nanoparticles
The in vitro evaluation for anti-Trypanosoma activity was
performed as previously described [8]. Briefly, T. congolense,
T. b. brucei and T. evansi were seeded at 1 105, 1 104 and
2 104 cells/mL, respectively, in a NuncTM 96-well optical
bottom plate (Thermo Fisher Scientific, Pittsburgh, PA) and
exposed to various concentrations of nanoparticles (0 to
10 lg/mL). The plates were incubated at 33 C (T. congolense)
and 37 C (T. b. brucei and T. evansi). After a 72 h-incubation,
25 lL of CellTiter-GloTM Luminescent Cell Viability Assay
reagent (Promega Japan, Tokyo, Japan) was added and the
plates were shaken for 2min using an MS3 basic plate shaker
(IKAVR Japan K.K., Osaka, Japan) to facilitate cell lysis and the
release of intracellular ATP. After a 10min-incubation at room
temperature, the ATP concentration was measured using a
GloMaxVR -MultiþDetection System plate reader (Promega
Japan). The experiments were carried out in triplicate.
Cytotoxicity of the nanoparticles in mammalian cells
The cell viability assays were as described elsewhere [3,28].
Briefly, Human foreskin fibroblast monolayers (HFF; ATCCVR ,
Manassas, VA) cultured in Dulbecco’s Modified Eagle Medium
(DMEM; Nissui, Tokyo, Japan) and supplemented with
GlutaMAXTM-I (Gibco, Invitrogen, Waltham, MA), 10% (v/v)
FBS (Gibco, Invitrogen, Waltham, MA) and penicillin and
streptomycin (10,000U/ml; Leicestershire, UK) were allowed
to grow to confluence at 37 C in a 5% CO2 atmosphere.
At confluence, the cells were harvested and seeded in clear
96-well plates (Nunc; Fisher Scientific, Pittsburgh, PA), at a
density of 1 105 cells per well. After a 72 h-incubation at
37 C in a 5% CO2 atmosphere, various concentrations of the
nanoparticles (0 to 10 lg/mL) were added. Culture medium
lacking the test compounds was added to the control well
and the medium only well was used for background correc-
tion. After a further 72 h-incubation at 37 C in a 5% CO2
atmosphere, cell viability was determined by use of the
CellTitre-Aqueous One Solution proliferation assay kit
(Promega, Madison, WI) following the manufacturer’s instruc-
tions. Briefly, the plates and their contents were equilibrated
to room temperature. Then, 20 ml of the CellTitre-Aqueous
One reagent was added to each well. The contents were
briefly mixed on an orbital shaker and then incubated at
37 C in a 5% CO2 atmosphere for 1–4 h. The absorbance
signal was recorded at 490 nm by using a microplate reader
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(MTP 500; Corona Electric, Hitachinaka Japan). The assay was
repeated three times, in triplicate.
Toxoplasma gondii parasite strain
A luciferase-expressing parasite strain, T. gondii RH-2F (ATCCVR
50839), was used for this study. The parasite was maintained
by repeated passages in monolayers of HFF cells (ATCCVR ,
Manassas, VA) cultured in DMEM (Nissui, Tokyo, Japan)
and supplemented with GlutaMAXTM-I (Gibco, Invitrogen,
Waltham, MA), 10% (v/v) FBS (Gibco, Invitrogen, Waltham,
MA) and penicillin and streptomycin (10,000U/ml;
Leicestershire, UK). The number of T. gondii tachyzoites
was determined by using a luminescence-based assay of
b-galactosidase (b-gal) activity expressed by the parasite
strain RH-2F. To obtain a purified parasite suspension for the
assays, infected cells were syringe-released using a 27-gauge
needle in order to lyse them. The lysates were passed
through a 5-mm filter to obtain parasite suspension free of
host cell debris. The parasite suspension was then washed
with fresh culture medium and parasite density was meas-
ured with a haemocytometer and adjusted for in vitro experi-
mental infection analysis.
Anti-T. gondii potential of nanoparticles in vitro
The nanoparticles were screened for in vitro anti-T. gondii
as previously described [3,28,31]. Briefly, purified parasite
suspension plus various concentrations of the nanoparticles
(0 to 10 lg/mL; reconstituted in culture medium prior to use)
were added to growing HFF monolayers in 96-well solid
white plates (Nunc; Fisher Scientific, Pittsburgh, PA).
Untreated but infected cells served as controls, whereas the
culture medium only well was used for background correc-
tion. Sulfadiazine (Sigma, St Louis, MO) and/or pyrimethamine
(Wako Pure Chemical, Osaka, Japan) were included as posi-
tive drug controls. After the 48-h incubation at 37 C in a 5%
CO2 atmosphere, the viability of the RH-2F parasite strain
was determined by assaying for b-gal activity by using a
Beta-Glo luminescent assay kit (Promega, Madison, WI). The
assay was performed in triplicate and repeated three times
independently.
In vivo experiments
Parasite strain
T. b. brucei (Lafia strain) adapted to animal experimental
trypanosomosis was used for this study. The Lafia strain of
T. b. brucei was originally obtained from the Department of
Veterinary and Livestock Studies, Nigerian Institute for
Trypanosomiasis Research (NITR), Vom, Nigeria. The parasite
was maintained by repeated passages in rats by inoculating
0.5ml of parasite suspension (approximately 106 trypano-
somes/ml) into the peritoneal cavity of uninfected rats. The
suspension usually contained 1 trypanosome per view at
10 40 magnification. Animals were inoculated with the
parasite and parasitaemia was monitored daily to establish
infection progress until the infected animals died.
Experimental animals
Male Wistar rats (weighting 150–160 g) were used as an
experimental model of trypanosomosis. Caution was taken to
ensure that all rats were germ- and disease-free. The animals
were sourced from the small animal unit of the Department
of Biochemistry, University of Ilorin, Nigeria. Animals were
acclimatized for two weeks before commencement of
the study.
Ethics statement
The animals were treated in accordance with approved
guidelines for the handling of experimental animals and
consistent with the International Guiding Principles for
Biomedical Research Involving Animals. Geneva, Switzerland:
(CIOMS) [32], under the observation of the local Institutional
Ethics Committee on Scientific Research with approval and
protocol 3152015.
Preliminary experiments
To establish the progress of infection in the animals, the rats
were randomly divided into two groups as follows:
Group A: Uninfected and control
Group B: Infected with T. b. brucei and untreated
Parasite load was monitored daily to establish the pro-
gress of infection, until day 6 post-infection when
infected animals died. To count the parasites, blood
smears were made by collecting fresh blood from the tail
vein of the animals and counting the parasites under a
light microscopy (10 40 magnification) using the match-
ing method of Herbert and Lumsden [33] as described
elsewhere [34].
Anti-Trypanosoma evaluation of nanoparticles in vivo
After establishing the trend of events during infection by
T. b. brucei, Wistar rats were assigned randomly into different
groups with at least six animals per group. All animals were
monitored daily for either parasite load or other physical
changes. Treatment was assessed by determining the degree
of reduction in parasite burden since parasite load correlates
with severity of infection. DMZ and nanoparticle treatment
commenced 96 h post-infection. Parasite load was monitored
daily as previously reported [34]. The groupings were
as follows:
Group 1: Uninfected and untreated
Group 2: Negative drug control (infected and untreated)
Group 3: Infected and treated with diminazene aceturate (DMZ;
3.5mg/kg bw)
Group 4: Infected and treated with either gold, silver or platinum
nanoparticles (5 mg/kg bw)
Group 5: Infected and treated with either gold, silver or platinum
nanoparticles (10mg/kg bw)
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Data analysis
Data were analysed by using a one-way ANOVA (GraphPad
Software Inc., San Diego, CA) and are presented as the
mean± SEM. Comparisons among groups were determined
by using a one-way ANOVA and Dunnett’s post hoc test.
p Values .05 were considered to be statistically significant
(GraphPad; CA). The concentration of the nanoparticles show-
ing a 50% reduction in parasite and/or mammalian cell viabil-
ity (i.e. EC50 and/or IC50 values) were estimated by using
Prism 5 (GraphPad; CA); non-linear regression analysis was
used to fit the curve. The % parasite load in the animals was
plotted as a function of the days/concentrations of nanopar-
ticle or drug used.
Results
The UV/Vis spectra and TEM images of the nanoparticles
(Figures 1 and 2) conform with earlier reports [23,26,27] and
thus confirm the successful synthesis of the nanoparticles.
The TEM images revealed the nanoparticles as spherical in
shape, while further analysis using ImageJ (National Institutes
of Health, Bethesda, MD) revealed that the particles were pol-
ydispersed with diameter size ranges of 5–50 nm.
To establish the anti-parasite activity and mammalian cell
cytotoxic potential of the nanoparticles (NPs), we screened
the inorganic NPs at various concentrations between 0 and
10mg/mL for anti-Trypanosoma activity by incubating fresh
parasite suspension (T. b. brucei, T. congolense and T. evansi)
with the NPs for 72 h under the indicated cell culture condi-
tions. Parasite growth curves were determined by measuring
the ATP concentrations of the viable parasites by using a
luminescence-based assay. To validate our assay for anti-
Trypanosoma screening, we included pentamidine as a refer-
ence drug. This drug significantly inhibited the growth of
Trypanosoma thus validating our assay. The NPs exhibited
differential anti-Trypanosoma potential among the three dif-
ferent species of Trypanosoma. For example, the gold and sil-
ver nanoparticles (AuNP and AgNP respectively) significantly
reduced T. b. brucei viability by 95% (Figure 3(A,B)), whereas
AuNP was less effective against T. congolense and T. evansi
with an average of 50% parasite growth inhibition. AgNP
reduced the growth of T. congolense and T. evansi by 70%,
suggesting that these NPs may have different parasite tar-
gets. Further, the platinum nanoparticles (PtNP) was only
effective against T. congolense (Figure 3(C)), with 50% para-
site growth inhibition. Although the NPs showed different
anti-Trypanosoma action against the three species, there is
no doubt that the anti-Trypanosoma activities of the NPs
were strongly selective toward the parasite. An estimation of
the ratio of the mammalian cell cytotoxic IC50 values to the
anti-parasite EC50 values as a measure of the anti-parasite
efficacy or selectivity index (SI) revealed a promising trend
(Table 1); the NPs showed 200-fold selectivity toward the
various species versus the mammalian cell, indicating that
the NPs may have specificity for Trypanosoma elimination.
Furthermore, it should be noted that the EC50 values of these
NPs are in the sub-microgram range.
Next, we asked whether combining the individual NPs as
alloys would increase their anti-Trypanosoma efficacy. We
screened NP alloys, including Ag-Au-Pt-NP, Ag-Pt-NP, Au-Pt-
NP and Ag-Au-NP, for their potential to inhibit Trypanosoma
growth. However, we found that the NP alloys failed to sup-
press parasite growth across the three species of
Trypanosoma, exhibiting an average of 50% parasite inhib-
ition (Figure 4(A–D)). This finding may indicate that these NP
alloys lack anti-Trypanosoma efficacy or that combining the
individual NPs as alloys reduces their individual anti-parasitic
action. Although, Ag-Au-NP moderately suppressed the
growth of T. b. brucei by an average of 60%, there was no
synergy among the NP activities when the NPs were com-
bined as alloys. Moreover, some of the NP alloys showed
Figure 1. UV/Vis absorbance spectra of nanoparticles (200–800 nm).
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Figure 2. Transmission electron microscopy (TEM) images of nanoparticles. Scale bar ¼100 nm.
Figure 3. In vitro anti-Trypanosoma activity of nanoparticles: (A) AuNP; (B) AgNP; (C) PtNP. Values are expressed as the meanþ standard error of the mean (SEM).
Growth viability of parasites was determined after a 72-h incubation at 33 C (T. congolense) or 37 C (T. b. brucei and T. evansi) using Luminescent Cell Viability
Assay reagent (Promega Japan, Tokyo, Japan). The experiment was repeated three times independently.
Table 1. Estimation of anti-parasitic efficacy of nanoparticles (lg/ml).
Compounds EC50 T. b. brucei EC50 T. congolense EC50 T. evansi EC50 T. gondii IC50 HFF Cells SI T. b. brucei SI T. congolense SI T. evansi SI T. gondii
AuNP 0.001 0.08 0.12 – 97.63 2000 1000 800 –
AgNP 0.001 0.06 0.08 – 32.71 2000 500 400 –
PtNP 0.20 79.58 0.02 – 9.27 45 10 2 –
Ag-Au-Pt-NP 0.22 0.06 0.17 0.15 0.22 2 10 6 2
Ag-Pt-NP 0.66 0.03 0.04 0.15 0.24 2 1 500 2
Au-Pt-NP 1.65 0.02 ND 5.75 1.18 1 50 ND 1
Ag-Au-NP ND 0.05 0.61 0.16 0.15 ND 5 1 1
AuNPTRP ND 0.07 0.65 – 6.80 ND 90 15 –
AgNPTRP ND 0.05 0.31 – 0.31 ND 10 1 –
Values presented are means (n¼ 3). The experiment was repeated three times independently. AuNP: gold nanoparticle; AgNP: silver nanoparticle; PtNP: platinum
nanoparticle; TRP: tryptophan.  ND: not determined, SI: selectivity index (SI¼ IC50 in mammalian cell divided by the EC50 in parasite.).
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increased cytotoxicity toward the mammalian cells (Table 1)
compared with the individual NPs. We previously reported
that AuNP, AgNP and PtNP have anti-T. gondii activity [3];
therefore, we sought to determine how the NP alloys would
affect T. gondii growth. All of the NP alloys moderately sup-
pressed the in vitro growth of T. gondii by 60% except for
Au-Pt-NP (Figure 5). This finding contrasts with the poor
anti-Trypanosoma activity exhibited by the same NP
alloys (Figure 4(A–D)). Although the NP alloys had good anti-
T. gondii activity, their selectivity toward the parasite versus
the host mammalian cell was poor (2-fold anti-parasitic
action). This is far less than the 20-fold selectivity earlier
reported for the anti-T. gondii action of the individual NPs
(AuNP, AgNP and PtNP). Sulfadiazine was included as refer-
ence drug for toxoplasmosis and, as expected, it restricted
the growth of T. gondii, thus validating our assay.
We also sought to determine the anti-Trypanosoma activ-
ity of AuNP- and AgNP-tryptophan conjugates. This was
premised on a recent report [28], that suggest that nanopar-
ticle-tryptophan conjugates (AuNPTRP and AgNPTRP) had
better anti-T. gondii activity than nanoparticles lacking this
amino acid. Therefore, we screened AuNPTRP and AgNPTRP for
anti-Trypanosoma activity. Interestingly, both AuNPTRP and
AgNPTRP appreciably suppressed the growth of T. b. brucei by
90% (Figure 6(A,B)), but had no effect against T. congolense
or T. evansi (20 and 40% parasite inhibition, respectively).
This result is comparable to the anti-Trypanosoma activities
of the NPs lacking l-tryptophan.
Lastly, we sought to evaluate the anti-Trypanosoma effi-
cacy of the NPs in vivo by using a rat model of experimental
infection. However, the results were not promising (Figure 7);
there was no appreciable decline in the parasite burden for
the NP-treated animals compared with the untreated control.
Although it appeared that the NPs were trypanostatic, the NP
treatments failed to clear the systemic parasite burden and
consequently the animals succumbed to their infections in a
manner comparable to the fate of the negative drug control
group. However, diminazene aceturate treatment (3.5mg/kg
bw) not only reduced the systemic parasite burden but also
significantly extended the survival time of the animals.
Discussion
The nanoscale size of nanoparticles confers unique and
remarkable properties, such as enhanced solubility and large
surface area-to-volume ratio, that can be explored for bio-
medical purposes [14]. Inorganic nanoparticles, such as silver
and gold, have been shown to possess interesting properties
such as anti-microbial activity [15,16,35], as well as the ability
to modulate enzyme activities [20–22]. Previously, we
reported the potential of AuNP and AgNP to selectively
inhibit recombinant target enzymes from T. b. brucei [23,24].
On the basis of this finding as a view toward seeking better
therapy for the treatment of trypanosomosis, we herein
investigated the anti-parasite potential of these nanoparticles
Figure 4. In vitro anti-Trypanosoma activity of nanoparticle alloy: (A) Ag-Au-Pt-NP; (B) Ag-Pt-NP; (C) Au-Pt-NP; (D) Ag-Au-NP. Values are expressed as the mean-
þ standard error of the mean (SEM). Growth viability of parasites was determined after a 72-h incubation at 33 C (T. congolense) or 37 C (T. b. brucei and T. evansi)
by using Luminescent Cell Viability Assay reagent (Promega Japan, Tokyo, Japan). The experiment was repeated three times independently.
Figure 5. In vitro anti-Toxoplasma gondii activity of nanoparticle alloys. Values
are expressed as the meanþ standard error of the mean (SEM). Parasite growth
inhibition was determined after a 48-h incubation at 37 C/5% CO2 by using a
luciferase reporter assay. The experiment was repeated three times
independently.
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in vitro and in vivo. As a proof-of-principle, in the present
study, we evaluated several nanoparticles (NPs) for their anti-
parasitic potential against different Trypanosoma species and
Toxoplasma gondii.
The NPs exhibited differential anti-Trypanosoma potential
among the three different species of Trypanosoma tested.
While AuNP was less effective against T. congolense and
T. evansi with an average of 50% parasite growth inhibition,
AgNP reduced the growth of T. congolense and T. evansi by
70%, suggesting that these NPs may have different parasite
targets. The finding that AuNP and AgNP showed better effi-
cacy against T. b. brucei may support exploring these NPs as
prospective treatment of the human type of trypanosomosis
caused by T. b. rhodiense and T. b. gambiense, given that
T. b. brucei belongs in the same group and is closer in terms
of morphological features to the human Trypanosoma patho-
gens. Taken together, AuNP and AgNP showed strong anti-
Trypanosoma activity, consistent with previously published
investigations of the anti-microbial and/or anti-parasite prop-
erties of AuNP and AgNP [3,16–19]. Similar studies using
PtNP are scarce in the literature except for our recent report
[3] that demonstrated the anti-T. gondii property of PtNP.
Moreover, our findings herein support our earlier reports that
AuNP and AgNP strongly and selectively inhibit recombinant
T. b. brucei arginine kinase [23,24]. Arginine kinase is a phos-
photransferase that is essential for the growth and survival of
T. b. brucei particularly in the bloodstream of the infected
host because it helps the parasite meet required energy
demands to maintain a reductive environment [23]. Whether
the NPs interact with this arginine kinase as a target in
suppressing the in vitro growth of Trypanosoma is yet to be
determined, but the previous finding [23] indicated that
arginine kinase might be a likely parasite target thus this
warrants further investigation. Further, because the field of
nanomedicine is still emerging, the modes of action of the
majority of NPs are yet to be clearly defined. Nevertheless,
studies have shown that the generation of reactive oxygen
species (ROS) contributes considerably to the anti-parasitic
action of NPs including AuNP, AgNP and others [3,36].
However, we cannot yet tell whether ROS production played
a part in the action of the NPs against Trypanosoma in the
present study. The differential efficacy of the NPs against the
different species studied here may be connected to their
mode of action, which would suggest that the NPs may
affect different parasite targets across the three species of
Trypanosoma investigated in this study. Furthermore, the NPs
showed 200-fold selectivity toward the various species ver-
sus the mammalian cell, suggesting that the NPs actually
have specificity for Trypanosoma elimination.
In contrast, alloys of these nanoparticles failed to suppress
parasite growth across all three species of Trypanosoma
tested, exhibiting an average of 50% parasite inhibition.
The reason for this is unknown, but it does suggest that
there is no synergy among the individual activities of the
NPs when combined together as NP alloys. Conversely, the
NP alloys moderately suppressed the in vitro growth of
T. gondii by 60%, except Au-Pt-NP. Taken together, these
findings indicate that AuNP, AgNP and PtNP are more effect-
ive individually than as alloys. Further, the findings suggest
that AuNP and AgNP have potential as candidates for the
treatment of Trypanosoma-related infection. This is the first
study reporting the anti-Trypanosoma activities of these inor-
ganic NPs and their alloys. Our findings herein support the
anti-parasitic action of these NPs and are consistent with pre-
viously reported findings [3,16–19,37–40]. As further confirm-
ation that inorganic NPs show promise as novel agents for
the treatment of T. b. brucei-related infection, AuNP- and
AgNP-tryptophan conjugates appreciably suppressed the
growth of T. b. brucei by 90% but had less activity against
T. congolense and T. evansi (20 and 40% parasite inhibition,
respectively). Whether this activity against T. b. brucei is
attributable to the presence of l-tryptophan remains to be
determined. However, recent findings from our laboratory
revealed that AuNP- and AgNP-tryptophan conjugates have
superior activity against T. gondii compared with ordinary
Figure 6. In vitro anti-Trypanosoma activity of nanoparticle-tryptophan conjugates: (A) AuNPTRP; (B) AgNPTRP. Values are expressed as the meanþ standard error of
the mean (SEM). Growth viability of parasites was determined after a 72-h incubation at 33 C (T. congolense) or 37 C (T. b. brucei and T. evansi) using Luminescent
Cell Viability Assay reagent (Promega Japan, Tokyo, Japan). The experiment was repeated three times independently.
Figure 7. Anti-Trypanosoma effect of nanoparticles in rats. Values are expressed
as the meanþ standard error of the mean (SEM, n¼ 5). Treatment commenced
at 96 h post-infection. Parasite burden was determined by counting the number
of parasites in blood smears (made by collecting fresh blood from the tail vein
of the animals) under a light microscope (100 magnification).
S92 O. S. ADEYEMI ET AL.
nanoparticles lacking the tryptophan [28]. It is likely that
since T. gondii is auxotrophic for l-tryptophan and must
therefore obtain it from the host in order to survive, the
parasite becomes more sensitive to AuNPTRP and AgNPTRP
leading to better anti-T. gondii activity compared with NPs
that lack l-tryptophan. Whether the same mechanism is
applicable in the present study is unclear. Although l-trypto-
phan is essential for the growth of trypanosomes, T. gondii is
an intracellular parasite whereas Trypanosoma is extracellular.
The NPs did not effectively reduce the rat systemic para-
site burden and consequently failed to extend the survival
time of the infected rats. Probably, the NP doses (0.02mg/
kg bw) used in the present study were too low to be effect-
ive in this rat model of experimental trypanosomosis. Our
future investigations would seek to determine the in vivo
anti-parasitic efficacy of these NPs by using higher doses
than those used in the current study. Several studies have
established that when orally administered, the LD50 for AuNP,
AgNP, as well as PtNP, is 500mg/kg [26,41,42].
In conclusion, this is the first study to report the anti-
Trypanosoma activity of inorganic NPs and their alloys. These
findings add support to the in vitro anti-parasitic action of
NPs against T. b. brucei, T. congolense and T. evansi. Our data
also indicate that NPs may be effective against both extracel-
lular and intracellular parasites. Although the present data do
not support the in vivo efficacy of these NPs, future investiga-
tions to determine the in vivo anti-Trypanosoma effectiveness
of these NPs at higher doses are warranted. Nevertheless,
the NPs exhibited promising and selective in vitro anti-
Trypanosoma action.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
The authors acknowledge the International Foundation for Science (IFS)
Grant F/5672 and the Japan Society for the Promotion of
Science Fellowship.
ORCID
Oluyomi Stephen Adeyemi http://orcid.org/0000-0001-9342-8505
References
[1] Creek DJ, Barret MP. Determination of antiprotozoal drug mecha-
nisms by metabolomics approaches. Parasitology. 2014;141:83–92.
[2] Adeyemi OS, Sulaiman FA. Biochemical and morphological
changes in Trypanosoma brucei brucei- infected rats treated with
homidium chloride and diminazene aceturate. J Basic Clin Physiol
Pharmacol. 2012;23:179–183.
[3] Adeyemi OS, Murata Y, Sugi T, et al. Inorganic nanoparticles
caused death of Toxoplasma gondii through alteration of
redox status and mitochondrial membrane potential. Int J
Nanomedecine. 2017;12:1647–1661.
[4] Adeyemi OS, Akanji MA, Ekanem JT. Anti-anaemic properties of
the ethanolic extracts of Psidium guajava in Trypanosoma brucei
brucei infected rats. Res J Pharmacol. 2010;4:74–77.
[5] Barrett MP, Boykin DW, Brun R, et al. Human African trypanosom-
iasis: pharmacological re-engagement with a neglected disease.
Br J Pharmacol. 2007;152:1155–1171.
[6] Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer
than melarsoprol for the treatment of second-stage Trypanosoma
brucei gambiense human African trypanosomiasis. Clin Infect Dis.
2005;41:748–751.
[7] Stijlemans B, Vankrunkelsven A, Brys L, et al. Role of iron homeo-
stasis in trypanosomiasis-associated anemia. Immunobiology.
2008;213:823–835.
[8] Molefe NI, Yamasaki S, Macalanda AMC, et al. Oral administration
of azithromycin ameliorates trypanosomosis in Trypanosoma con-
golense-infected mice. Parasitol Res. 2017;116:2407–2415.
[9] Blum J, Nkunku S, Burri C. Clinical description of encephalopathic
syndromes and risk factors for their occurrence and outcome dur-
ing melarsoprol treatment of human African trypanosomiasis.
Trop Med Int Health. 2001;6:390–400.
[10] World Health Organization. Control and surveillance of African
trypanosomiasis: report of a WHO Expert Committee. World
Health Organ Tech Rep Ser. 1998;881(I-VI):1–114.
[11] Gupta S, Igoillo-Esteve M, Michels PAM, et al. Glucose-6-phos-
phate dehydrogenase of trypanosomatids: characterization, target
validation, and drug discovery. Mol Biol Int. 2011;2011:135701.
[12] Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii.
Microbiol Mol Biol Rev. 2000;64:607–623.
[13] Kamau ET, Srinivasan AR, Brown MJ, et al. A focused small-mol-
ecule screen identifies 14 compounds with distinct effects on
Toxoplasma gondii. Antimicrob Agents Chemother. 2012;56:
5581–5590.
[14] Adeyemi OS, Sulaiman FA. Evaluation of metal nanoparticles for
drug delivery systems. J Biomed Res. 2015;29:145–149.
[15] MubarakAli D, Thajuddin N, Jeganathan K, et al. Plant extract
mediated synthesis of silver and gold nanoparticles and its anti-
bacterial activity against clinically isolated pathogens. Colloids
Surf B Biointerfaces. 2011;85:360–365.
[16] Lekshmi NCJ, Sumi SB, Viveka S, et al. Antibacterial activity of
nanoparticles from Allium sp J. Microbiol Biotech Res. 2012;2:
115–119.
[17] Bhardwaj R, Saudagar P, Dubey VK. Nanobiosciences: a contem-
porary approach in antiparasitic drugs. Mol Cell Pharmacol.
2012;4:97–103.
[18] Das S, Bhattacharya A, Debnath N, et al. Nanoparticle-induced
morphological transition of Bombyx mori nucleopolyhedrovirus: a
novel method to treat silkworm grasserie disease. Appl Microbiol
Biotechnol. 2013;97:6019–6030.
[19] Rahul S, Chandrashekhar P, Hemant B, et al. In vitro antiparasitic
activity of microbial pigments and their combination with phyto-
synthesized metal nanoparticles. Parasitol Int. 2015;64:353–356.
[20] Wigginton NS, Titta A, Piccapietra F, et al. Binding of silver nano-
particles to bacterial proteins depends on surface modifications
and inhibits enzymatic activity. Environ Sci Technol. 2010;44:
2163–2168.
[21] Salma AA, Amer HA, Shaemaa HA, et al. The effects of gold and
silver nanoparticles on transaminase enzymes activities. Int J
Cancer. 2011;3:2249–2329.
[22] Srivastava M, Singh S, Self WT. Exposure to silver nanoparticles
inhibits selenoprotein synthesis and the activity of thioredoxin
reductase. Environ Health Perspect. 2012;120:56–61.
[23] Adeyemi OS, Whiteley CG. Interaction of nanoparticles with argin-
ine kinase from Trypanosoma brucei: kinetic and mechanistic
evaluation. Int J Biol Macromol. 2013;62:450–456.
[24] Adeyemi OS, Whiteley CG. Interaction of metal nanoparticles with
recombinant arginine kinase from Trypanosoma brucei: thermo-
dynamic and spectrofluorimetric evaluation. Biochim Biophys
Acta. 2014;1840:701–706.
[25] Adeyemi OS, Murata Y, Sugi T, et al. Modulation of host HIF-1a
activity and the tryptophan pathway contributes to the anti-
Toxoplasma gondii potential of nanoparticles. Biochem Biophys
Rep. 2017;11:84–92.
ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY S93
[26] Adeyemi OS, Sulaiman FA, Akanji MA, et al. Biochemical and mor-
phological changes in rats exposed to platinum nanoparticles.
Comp Clin Pathol. 2016;25:855–864.
[27] Pal A, Shah S, Devi S. Microwave-assisted synthesis of silver nano-
particles using ethanol as a reducing agent. Mater Chem Phy.
2009;114: 530–532.
[28] Adeyemi OS, Murata Y, Sugi T, et al. Exploring amino acid-capped
nanoparticles for selective anti-parasitic action and improved host
biocompatibility. J Biomed Nanotechnol. 2018;14:847–867.
[29] Sivaraman SK, Elango I, Kumar S, et al. A green protocol for room
temperature synthesis of silver nanoparticles in seconds. Curr Sci.
2009;97:1055–1059.
[30] Hirumi H, Hirumi K. In vitro cultivation of Trypanosoma congolense
bloodstream forms in the absence of feeder cell layers.
Parasitology. 1999;102:225–236.
[31] Ishiwa A, Kobayashi K, Takemae H, et al. Effects of dextran sul-
fates on the acute infection and growth stages of Toxoplasma
gondii. Parasitol Res. 2013;112:4169–4176.
[32] Council for International Organizations of Medical Sciences.
International guiding principles for biomedical research
involving animals. Geneva, Switzerland: Council for International
Organizations of Medical Sciences (CIOMS); 1985.
[33] Herbert WJ, Lumsden WHR. Trypanosoma brucei: a rapid
“matching” method for estimating the host's parasitemia. Exp
Parasitol. 1976;40:427–431.
[34] Adeyemi OS, Ekanem JT, Sulyman F. Depletion of parasitaemia by
halofantrine hydrochloride and artemether in rats infected with
African trypanosomes. Afr J Pharm Pharmacol. 2009;3:432–438.
[35] Butkus MA, Labare MP, Starke JA, et al. Use of aqueous silver to
enhance inactivation of coliphage MS-2 by UV disinfection. Appl
Environ Microbiol. 2004; 70:2848–2853.
[36] Saini P, Saha SK, Roy P, et al. Evidence of reactive oxygen species
(ROS) mediated apoptosis in Setaria cervi induced by green silver
nanoparticles from Acacia auriculiformis at a very low dose.
Exp Parasitol. 2016;160:39–48.
[37] Ahmad A, Syed F, Shah A, et al. Silver and gold nanoparticles
from Sargentodoxa cuneata: synthesis, characterization and anti-
leishmanial activity. RSC Adv. 2015;5:73793–73806.
[38] Saad AHA, Soliman MI, Azzam AM. Antiparasitic activity of silver
and copper oxide nanoparticles against Entamoeba Histolytica
and Cryptosporidium Parvum cysts. J Egypt Soc Parasitol. 2015;45:
593–602.
[39] Francis S, Joseph S, Koshy EP, et al. Microwave assisted green syn-
thesis of silver nanoparticles using leaf extract of elephantopus
scaber and its environmental and biological applications. Artif
Cells Nanomed Biotechnol. 2018;46:795–804.
[40] Vijayan R, Joseph S, Mathew B. Indigofera tinctoria leaf extract
mediated green synthesis of silver and gold nanoparticles and
assessment of their anticancer, antimicrobial, antioxidant and
catalytic properties. Artif Cells Nanomed Biotechnol. 2018;46:
861–871.
[41] Adeyemi OS, Faniyan T. Antioxidant status in rats orally adminis-
tered silver nanoparticle. J Taibah Uni Med Sci. 2014;9:182–186.
[42] Maneewattanapinyo P, Banlunara W, Thammacharoen C, et al. An
evaluation of acute toxicity of colloidal silver nanoparticles. J Vet
Med Sci. 2011;73:1417–1423.
S94 O. S. ADEYEMI ET AL.
